Available Technologies
# of Displayed Technologies: 10 / 42
Applied Category Filter (Click To Remove): Oncology
Dual-payload Humanized Antibody-Drug Conjugate (DualADC) for targeted chemo-immunotherapy
TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types
The Technology
Dr. Margaret Liu and colleagues have developed a dual-payload antibody-drug conjugate (DualADC) for chemo-immunotherapy utilizing a new humanized antibody that targets CD276, a surface receptor that is overexpressed in Triple-negative Breast Cancers (TNBCs), lung cancer (including non…
- College: College of Engineering (COE)
- Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
- Licensing Officer: Schworer, Adam
Tracking Breast Tissue Tumor Cavity after Lumpectomy
TS-062715 — Radiopaque biodegradable polymer for the tracking of the breast tissue tumor cavity after lumpectomy and other radiation therapy applications
Approximately 40% of women diagnosed with breast cancer undergo a lumpectomy procedure. Approximately 170,000 lumpectomie are performed each yaer in the United States. Typically, this operation is followed by radiation therapy to ensure there are no remaining cancerous cells in the region. It is t…
- College: College of Engineering (COE)
- Inventors: Metzler, Sandra; Elisha, Deji; Evans, Izzy; Fedro, Joseph; Krakovsky, Mia; Sherry, Adam; Skoracki, Roman
- Licensing Officer: Zinn, Ryan
Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males.
The Need
Despite the crucial role of androgen receptors (AR) in HCC progress…
- College: College of Pharmacy
- Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
- Licensing Officer: Schultz, Teri
Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Pharmacy
- Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
- Licensing Officer: Taysavang, Panya
E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
- College: OSU Wexner Medical Center
- Inventors: Bennett, Chad; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
- College: College of Pharmacy
- Inventors: Bennett, Chad; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Medicine (COM)
- Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need:
Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
- College: College of Pharmacy
- Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
- Licensing Officer: Schworer, Adam
